Search

Background: Hemorrhagic myocardial infarction (hMI) can rapidly diminish the benefits of reperfusion therapy and direct the heart toward chronic heart failure. T2∗ cardiac magnetic resonance (CMR) is the reference standard for detecting hMI. However, the lack of clarity around the earliest time point for detection, time-dependent changes in hemorrhage volume, and the optimal methods for detection can limit the development of strategies to manage hMI., Objectives: The authors investigated CMR signal characteristics of hMI through time-lapse multiparametric mapping using a clinically relevant animal model and evaluated the translatability in ST-segment elevation MI patients when possible., Methods: Canines (N = 20) underwent 3.0-T CMR at baseline and various time points over the first week of reperfused MI. Time-dependent relationships between T1, T2, and T2∗ mapping of hMI, non-hMI, and remote territories were determined. Reperfused ST-segment elevation MI patients (N = 50) were studied to establish clinically feasibility., Results: Although hMI was evident <1 hour after reperfusion on histopathology, it was not reliably detected with T1, T2, or T2∗ CMR. However, 24 hours to 7 days postreperfusion, hMI was detectable on T2∗ (27.0 ± 2.4 ms [baseline] vs 11.7 ± 2.8 ms [hMI]; P < 0.001), with stable volume and transmurality. In T2 maps, hMI was most visible 5 to 7 days postreperfusion with an area under the curve of 0.98 (sensitivity and specificity ≥0.95) relative to T2∗. However, this was not the case with T1 (sensitivity <0.8, across all time points)., Conclusions: HMI cannot be reliably detected with T1, T2, or T2∗ on 3.0-T CMR immediately after reperfusion. However, T2∗ CMR can be used to diagnose hMI between 24 hours and 7 days postreperfusion. T2 maps at 3.0-T are a strong alternative to T2∗ maps for diagnosing hMI, provided CMR is performed 5 to 7 days postreperfusion. However, diagnosing hMI with T1 is significantly more challenging at 3.0-T compared with both T2∗ and T2., Competing Interests: Funding Support and Author Disclosures This work was supported in part by National Institutes of Health/National Heart, Lung, Blood Institute grants HL133407, HL136578, and HL147133 (Dr Dharmakumar) and HL169877 (Dr Z. Chen). Dr Z. Chen has received support from American Heart Association (23TPA1069000) and from the National Natural Science Foundation of China (grant number 81701643) and Shanghai Pujiang Program (grant number 21PJD012). Dr Zeng has received support from the Joint Research Development Project between Shenkang and United Imaging on Clinical Research and Translation (grant number SKLY2022CRT201). Dr Dharmakumar has ownership interest in Cardio-Theranostics, LLC. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2025 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)

For the purposes of this guideline, a diving accident is defined as an event that is either potentially life-threatening or hazardous to health as a result of a reduction in ambient pressure while diving or in other hyperbaric atmospheres with and without diving equipment. This national consensus-based guideline (development grade S2k) presents the current state of knowledge and recommendations on the diagnosis and treatment of diving accident victims. The treatment of a breath-hold diver as well as children and adolescents does not differ in principle. In this regard only unusual tiredness and itching without visible skin changes are mild symptoms. The key action statements: on-site 100% oxygen first aid treatment, immobilization/no unnecessary movement, fluid administration and telephone consultation with a diving medicine specialist are recommended. Hyperbaric oxygen therapy (HBOT) remains unchanged as the established treatment in severe cases, as there are no therapeutic alternatives. The basic treatment scheme recommended for diving accidents is hyperbaric oxygenation at 280 kPa., Competing Interests: See Attachment 2, (Copyright © 2023 Jüttner et al.)

Background: High plasma fibrin clot strength (MA) measured by thrombelastography (TEG) is associated with increased risk of cardiac events after percutaneous coronary interventions (PCIs). Factor XIIIa (FXIIIa) cross-links soluble fibrin, shortens clot formation time (TEG-K), and increases final clot strength (MA)., Methods: We analyzed platelet-poor plasma from patients with previous PCI. Kaolin-activated TEG (R, K, MA) in citrate platelet-poor plasma and FXIIIa were measured ( n = 257). Combined primary endpoint was defined as recurrent myocardial infarction (MI) or cardiovascular death (CVD). Relationship of FXIIIa and TEG measurements on cardiac risk was explored., Results: FXIIIa correlated with TEG-MA ( p = 0.002) and inversely with TEG-K ( p < 0.001). High MA (≥35.35 mm; p = 0.001), low K (<1.15 min; p = 0.038), and elevated FXIIIa (≥83.51%; p = 0.011) were associated with increased risk of CVD or MI. Inclusion of FXIIIa activity and low TEG-K in risk scores did not improve risk prediction as compared with high TEG-MA alone., Conclusion: FXIIIa is associated with higher plasma TEG-MA and low TEG-K. High FXIIIa activity is associated with a modest increase in cardiovascular risk after PCI, but is less sensitive and specific than TEG-MA. Addition of FXIIIa does not provide additional risk stratification beyond risk associated with high fibrin clot strength phenotype measured by TEG., Competing Interests: Conflict of Interest R.P.K. has served as consultant for Haemonetics Corporation and Roche Diagnostics.

Background: Patients with diabetes mellitus (DM) exhibit increased risk of recurrent myocardial infarction. Maximal clot strength measured by thrombelastography (TEG) is a risk factor for recurrent ischemic events. We hypothesized that diabetic subjects exhibit increased fibrin clot strength in platelet-poor plasma and that glycemic control correlates with maximal fibrin clot strength., Methods: We collected plasma samples from subjects with known or suspected coronary artery disease undergoing cardiac catheterization ( n = 354). We measured kaolin-activated TEG in platelet-poor citrate plasma. Time to fibrin formation (R), clot formation time (K), and maximal fibrin clot strength (MA) were recorded., Results: Plasma fibrin MA was increased among subjects with DM ( n = 152) as compared to non-DM ( n = 202) (37.0 ± 8 versus 34.1 ± 8 mm; p < 0.001). Hemoglobin A1c (HbA1c) ( ρ = 0.22; p = 0.001) and fibrinogen ( ρ = 0.29; p < 0.001) correlated with fibrin MA. In multivariable regression analysis, DM remained significantly associated with plasma MA after adjustment for fibrinogen level ( p = 0.003)., Conclusions: Subjects with diabetes mellitus exhibit increased maximal fibrin clot strength measured by TEG in platelet-poor plasma.

Cadherin-11/Cdh11 is expressed through early development and strongly during inner ear development (otic placode and vesicle). Here we show that antisense knockdown of Cdh11 during early zebrafish development interferes with otolith formation. Immunofluorescence labeling showed that Cdh11 expression was concentrated on and within the otolith. Cdh11 was faintly detected at the lateral surface (sites of cell-cell contact) of otic epithelial cells and in the cytoplasm. Strongly labeled Cdh11 containing puncta were detected within the otolymph (the fluid within the otic vesicle) and associated with the otolith surface. BODIPY-ceramine-labeled vesicular structures detected in the otolymph were larger and more numerous in Cdh11 knockdown embryos. We present evidence supporting a working model that vesicular structures containing Cdh11 (perhaps containing biomineralization components) are exported from the otic epithelium into the otolymph, adhere to one another and to the surface of the growing otolith, facilitating otolith growth., (Copyright (c) 2009 Wiley-Liss, Inc.)

Between 1981 and 1983 48 patients with an average age of 54 years have had an arterial embolization of internal iliac artery. In 7 patients this was done preoperatively within a clinical study, in 41 ones because of profuse vaginal bleedings. In 6 patients there was a vital indication. In all cases survival time was 152 days. In two cases a re-embolization was necessary. In these two patients survival time was on average 338 days. The manoeuvre was done with particles of gelatin of different size suspended in contrast medium. One complication could be observed, but was not caused directly by embolization. In cases of profuse or vital bleedings which conservatively cannot be stopped embolization is method of first choice with no contraindication.

Unlabelled: The efficiency of NEA (norethisteronacetate) as an adjuvant hormone therapy in 196 pat. suffering from endometrial cancer has been evaluated in a prospective randomized trial. Primarily 93 patients had been operated on and 103 ones irradiated. From these 45 patients following surgery and 51 ones following radiation therapy had been treated with NEA. Schedule of adjuvant NEA therapy was for a time 6 ms 50 mg/d followed by 6 ms pause and so on till 5 years post op. 5 years survival in the operation group was 91.7 per cent without and 81.6 per cent with NEA, in the irradiated group 43.1 per cent and 44.8 per cent respectively. Side effect (47.9%) were caused by NEA at least twice higher than in control groups., In Conclusion: the adjuvant hormone treatment without hormone receptor analysis is not recommendable.

It is reported about the application of bleomycin within a randomized prospective investigation. Bleomycin was used for additional chemo-therapy at the vulva-carcinoma. There were treated with Bleomycin 27 of 55 women from two gynaecological hospitals. -- After a period of two years and a half there can not be shown by the "life-table-method" advantage neither in comparison to the only surgical therapy not to the cryo-surgical treatment.

Disorders of the ovarian function after going off hormonal contraceptives are a serious complication when appearing as postpill amenorrhea in young nullipara. We could diagnose a postpill amenorrhea in 31 cases out of 52 patients suffering from functional ovarian disorders after stopping the application of hormonal contraceptives. 19 woman younger than 28 years and wanting to get pregnant had begun as adolescents to take contraceptive drugs. Concerning the etiology of post-pill amenorrhea the type of contraceptive is of importance as well as predisposing factors such as late menarche, unstable menstruation and other cycle anomalies. Our patients majority had taken gestagen-accentuated combination drugs. During adolescent age there should be prescribed only sequential drugs if necessary.